Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evome Medical Technologies Inc LNDZF


Primary Symbol: V.EVMT

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Comment by Zibo510on Jan 18, 2024 8:36am
61 Views
Post# 35833132

RE:New Press Release - Salona Global Finalizes Name Change to Evome Medical Technologies to Reflect Turn Around and New Innovation Focus; Restructures Board of Directors

RE:New Press Release - Salona Global Finalizes Name Change to Evome Medical Technologies to Reflect Turn Around and New Innovation Focus; Restructures Board of Directors
  • 29% gross profit growth for the quarter ending September 30, 2023 (compared to the previous quarter), management expects gross profit growth to continue into 2024.
  • Generated positive Adjusted EBTDA ‎(defined below) ‎of $749,425 for the quarter ending September 30, 2023, management expects positive Adjusted EBITDA growth to continue into 2024
<< Previous
Bullboard Posts
Next >>